HOCL is currently used in hospitals as a wound care agent. Several promising research studies have been done to suggest this molecule can do more than we currently know. Now that it is readily available, trials on patients with vulvadynia and/or chronic yeast infections could be conducted to confirm its' healing properties for these specific conditions. It would be expected that patients would see noticeable symptom relief and reduced severity and occurrence of outbreaks.
Idea No. 832